Objective:To investigate the scope and changes in the outcome of Keshan disease in Jilin Province, and provide scientific basis for adjusting the focus of Keshan disease prevention and control.Methods:A retrospective analysis was conducted on the annual report data of Keshan disease reported by 38 Keshan disease endemic counties (cities, districts) in Jilin Province from 2017 to 2021. Descriptive analysis was conducted on the scope of Keshan disease endemic areas, population, general situation and outcomes of current patients.Results:As of the end of 2021, there was no overall change in the scope of Keshan disease endemic areas in Jilin Province. The number of permanent residents in counties, townships, and villages in the endemic areas had decreased by 11.77%, 26.77%, and 35.55%, respectively, compared to 2017. There were a total of 1 092 current patients with Keshan disease, including 926 cases of latent Keshan disease and 166 cases of chronic Keshan disease. The male to female ratio was 0.38∶1.00 (303∶789), and 79.76% (871/1 092) of the patients were over 60 years old. Some patients also had other chronic diseases such as hypertension and coronary heart disease. In 2021, the number of patients with Keshan disease decreased by 1 020 compared to 2017. Death, migration (in), loss of follow-up, and re-diagnosis accounted for 34.29% (500/1 458), 27.85% (406/1 458), 25.51% (372/1 458), and 12.35% (180/1 458) of the total number of outcomes, respectively; 57 middle-aged and young patients under 60 years old accounted for 11.40% (57/500) of the total deaths. Over the past 5 years, 24 new patients were discovered, including 4 cases of latent Keshan disease and 20 cases of chronic Keshan disease. Additionally, 6 patients with chronic Keshan disease died within 2 years of diagnosis.Conclusions:The overall scope of Keshan disease endemic areas in Jilin Province has not changed, with a significant decrease in the number of permanent residents, an aging population of current patients, and some patients coexisting with chronic diseases. Death, migration (in), and loss of follow-up are the main outcomes of current patients.